高级检索
    黄诚, 林根, 雷源源. EGFR 19 Del的晚期非小细胞肺癌患者一线服用EGFR-TKIs的无进展生存期长于EGFR L858R患者[J]. 循证医学, 2015, 15(1): 25-28. DOI: 10.3969/j.issn.1671-5144.2015.01.009
    引用本文: 黄诚, 林根, 雷源源. EGFR 19 Del的晚期非小细胞肺癌患者一线服用EGFR-TKIs的无进展生存期长于EGFR L858R患者[J]. 循证医学, 2015, 15(1): 25-28. DOI: 10.3969/j.issn.1671-5144.2015.01.009
    shu
    HUANG Cheng, LIN Geng, LEI Yuan-yuan. Patients with Exon 19 Deletion Were Associated with Longer Progression?Free Survival Compared to Those with L858R Mutation after First?Line EGFR?TKIs for Advanced Non?Small Cell Lung Cancer[J]. Journal of Evidence-Based Medicine, 2015, 15(1): 25-28. DOI: 10.3969/j.issn.1671-5144.2015.01.009
    Citation: HUANG Cheng, LIN Geng, LEI Yuan-yuan. Patients with Exon 19 Deletion Were Associated with Longer Progression?Free Survival Compared to Those with L858R Mutation after First?Line EGFR?TKIs for Advanced Non?Small Cell Lung Cancer[J]. Journal of Evidence-Based Medicine, 2015, 15(1): 25-28. DOI: 10.3969/j.issn.1671-5144.2015.01.009
    shu

    EGFR 19 Del的晚期非小细胞肺癌患者一线服用EGFR-TKIs的无进展生存期长于EGFR L858R患者

    Patients with Exon 19 Deletion Were Associated with Longer Progression?Free Survival Compared to Those with L858R Mutation after First?Line EGFR?TKIs for Advanced Non?Small Cell Lung Cancer

      摘要
    • 摘要: 随着EGFR-TKIs在EGFR活性突变NSCLC患者中的广泛应用, 以往一些单中心研究发现EGFR-TKIs 针对EGFR 19 Del患者的治疗疗效可能要优于L858R突变患者, 但也存在不一致的研究结果。随着相关治疗数据的积累, 应用Meta分析进一步探明这一现象也就应运而生。

       

      • HTML全文
      • 参考文献(2)
      • 相关文章
      • 施引文献
    • 资源附件(0)

    /

    返回文章
    返回